Drug-eluting stents and balloons in peripheral arterial disease: Evidence so far

International Journal of Clinical Practice

Volumn 65, Issue 6, 2011, Pages 664-668

  Chan, Y C ^a   Cheng, S W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; NITINOL; PACLITAXEL; RAPAMYCIN;

ARTERY LESION; BARE METAL STENT; CRITICAL LIMB ISCHEMIA; DRUG ELUTING STENT; HUMAN; IN-STENT RESTENOSIS; INFRAPOPLITEAL LESION; LIMB ISCHEMIA; OUTCOMES RESEARCH; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PRIORITY JOURNAL; REVIEW; SAFETY; SUPERFICIAL FEMORAL ARTERY; SYSTEMATIC REVIEW; VASCULAR PATENCY;

ANGIOPLASTY, BALLOON; ATHEROSCLEROSIS; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HUMANS; ISCHEMIA; LEG; PERIPHERAL ARTERIAL DISEASE; RECURRENCE;

EID: 79956068293     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02639.x     Document Type: Review

References (27)

1. Stansby G, Chan YC, Berwanger CS, Shurey S, Rook GA, Stanford JL,. Prevention of experimental myointimal hyperplasia by immunomodulation. Eur J Vasc Endovasc Surg 2002; 23: 23-8. (Pubitemid 41079203)
2. Clowes AW, Reidy MA,. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia-a review. J Vasc Surg 1991; 13: 885-91.
3. Muradin GS, Bosch JL, Stijnen T, Hunink MG,. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology 2001; 221: 137-45. (Pubitemid 32880382)
4. Liuzzo JP, Ambrose JA, Coppola JT,. Sirolimus- and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization. J Invasive Cardiol 2005; 17: 497-502.
5. Morice MC, Serruys PW, Sousa JE, et al., Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. N Engl J Med 2002; 346: 1773-80.
6. Morice MC, Serruys PW, Barragan P, et al., Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007; 50: 1299-304. (Pubitemid 47454687)
7. Moses JW, Leon MB, Popma JJ, et al., Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23. (Pubitemid 37186209)
8. Stone GW, Ellis SG, Cannon L, et al., Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294: 1215-23. (Pubitemid 41352109)
9. Silber S, Colombo A, Banning AP, et al., Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation 2009; 120: 1498-504.
10. Duda SH, Pusich B, Richter G, et al., Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002; 106: 1505-9.
11. Duda SH, Bosiers M, Lammer J, et al., Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006; 13: 701-10. (Pubitemid 44907633)
12. Dake M,. Interim Report on the Zilver PTX Trial. Presented at 2009 Charing Cross Symposium, London, UK. Text in Machan L. Debate 6: DES in The SFA Will Have A Positive Impact. (accessed April 2009)
13. Dake M,. Interim Analysis of Two-year Results for the Zilver PTX Drug-eluting Peripheral Stent. Presented at: 2009 Vascular Annual Meeting; June 11-14, 2009; Denver, CO.
14. Bosiers M, Deloose K, Verbist J, Peeters P,. Percutaneous transluminal angioplasty for the treatment of below-the-knee critical limb ischemia: early outcomes following the use of sirolimus-eluting stents. J Cardiovasc Surg (Torino) 2006; 47: 171-6.
15. Scheinert D, Ulrich M, Scheinert S, Sax J, Bräunlich S, Biamino G,. Comparison of sirolimus-eluting vs. bare-metal stents for the treatment of infrapopliteal obstructions. Eurointervention 2006; 2: 169-74.
16. Commeau P, Barragan P, Roquebert PO,. Sirolimus for below the knee lesions: mid-term results of SiroBTK study. Cathet Cardiovasc Interv 2006; 68: 793-8. (Pubitemid 44721107)
17. Siablis D, Kraniotis P, Karnabatidis D, Kagadis GC, Katsanos K, Tsolakis J,. Sirolimus-eluting versus bare metal stents for bailout after suboptimal infrapopliteal angioplasty for chronic limb ischemia: 6 month angiographic results from a nonrandomized prospective single-center study. J Endovasc Ther 2005; 12: 685-95. (Pubitemid 43100926)
18. Siablis D, Karnabatidis D, Katsanos K, et al., Sirolimus-eluting versus bare stents for after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit. J Endovasc Ther 2007; 14: 241-50. (Pubitemid 46776123)
19. Siablis D, Karnabatidis D, Katsanos K, et al., Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol 2009; 20: 1141-50.
20. van der Giessen WJ, Lincoff AM, Schwartz RS, et al., Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-7. (Pubitemid 26320276)
21. Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G,. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004; 110: 810-4. (Pubitemid 39096008)
22. Tepe G, Zeller T, Albrecht T, et al., Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008; 358: 689-99. (Pubitemid 351240748)
23. Werk M, Langner S, Reinkensmeier B, et al., Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008; 118: 1358-65.
24. Nebeker JR, Virmani R, Bennett CL, et al., Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47: 175-81. (Pubitemid 43005183)
25. Mintz GS, Shah VM, Weissman NJ,. Regional remodeling as the cause of late stent malapposition. Circulation 2003; 107: 2660-3. (Pubitemid 36667237)
26. Sharma S, Kukreja N, Christopoulos C, Gorog DA,. Drug-eluting balloon: new tool in the box. Expert Rev Med Devices 2010; 7: 381-8.
27. Bosiers M, Cagiannos C, Deloose K, Verbist J, Peeters P,. Drug-eluting stents in the management of peripheral arterial disease. Vasc Health Risk Manag 2008; 4: 553-9. (Pubitemid 352037915)